PharmaCyte Biotech, Inc. (PMCB)
NASDAQ: PMCB · Real-Time Price · USD
1.220
+0.010 (0.83%)
At close: Dec 5, 2025, 4:00 PM EST
1.150
-0.070 (-5.74%)
After-hours: Dec 5, 2025, 7:59 PM EST
PharmaCyte Biotech Income Statement
Financials in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
| TTM
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Jul '25 Jul 31, 2025 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 |
| Selling, General & Admin | 3.52 | 3.94 | 6.11 | 5.99 | 3.7 | 2.71 | |
| Research & Development | 0.44 | 0.44 | 0.41 | 0.47 | 0.69 | 0.92 | |
| Operating Expenses | 3.96 | 4.38 | 6.52 | 6.46 | 4.39 | 3.62 | |
| Operating Income | -3.96 | -4.38 | -6.52 | -6.46 | -4.39 | -3.62 | |
| Interest Expense | - | - | - | - | -0 | -0 | |
| Interest & Investment Income | 1.09 | 1.42 | 3.4 | 1.94 | 0.16 | - | |
| Other Non Operating Income (Expenses) | 2.55 | 9.11 | 5.45 | 0.2 | -0 | -0 | |
| EBT Excluding Unusual Items | -0.33 | 6.15 | 2.33 | -4.32 | -4.24 | -3.63 | |
| Gain (Loss) on Sale of Investments | 1.22 | 26.53 | - | - | - | - | |
| Asset Writedown | - | - | -2 | - | - | - | |
| Legal Settlements | -2.02 | -2.02 | - | - | - | - | |
| Other Unusual Items | - | - | - | - | - | 0.08 | |
| Pretax Income | -1.13 | 30.66 | 0.33 | -4.32 | -4.24 | -3.55 | |
| Net Income | -1.13 | 30.66 | 0.33 | -4.32 | -4.24 | -3.55 | |
| Preferred Dividends & Other Adjustments | -1.17 | 7.29 | 17.57 | - | - | - | |
| Net Income to Common | 0.04 | 23.36 | -17.24 | -4.32 | -4.24 | -3.55 | |
| Net Income Growth | - | 9084.98% | - | - | - | - | |
| Shares Outstanding (Basic) | 7 | 7 | 10 | 19 | 16 | 1 | |
| Shares Outstanding (Diluted) | 7 | 7 | 10 | 19 | 16 | 1 | |
| Shares Change (YoY) | -15.90% | -23.50% | -50.84% | 25.56% | 971.73% | 60.24% | |
| EPS (Basic) | 0.01 | 3.19 | -1.80 | -0.22 | -0.27 | -2.45 | |
| EPS (Diluted) | 0.01 | 3.19 | -1.80 | -0.22 | -0.27 | -2.45 | |
| EBIT | -3.96 | -4.38 | -6.52 | -6.46 | -4.39 | -3.62 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.